Wow....Uddin notably absent and Stedman clearly taken abackLoe and Abrahms seem on top of the story and I think we’ll see good reports out of them.
Hopefully, Stedman walks back his comments from the other day and Uddin simply drifts off in to the ether.
They have a clear plan for NASH and F8 will be the drug for a large non-HIV NASH study in the future.
In the near term, we should see increased Egrifta scripts and that trend should continue with further data presentation. As I mentioned before, going from cosmetic to therapeutic is big.
European Trogarzo approval is important as the synergy of launching Trogarzo and Egrifta there would be huge.
bfw